Abstract 1442P
Background
We previously reported that intratumoral HER2 heterogeneity was associated with limited treatment efficacy to trastuzumab-based chemotherapy for HER2 positive advanced gastric cancer (AGC). In this study, we investigated the mechanism of resistance associated with intratumoral HER2 heterogeneity through ctDNA analysis.
Methods
We enrolled tissue-confirmed HER2 positive AGC patients who received chemotherapy with anti-HER2 and anti-PD-1 dual-targeted therapy from a phase Ib clinical trial. We compared clinical characteristics, gene alterations that obtained by ctDNA panel (Guardant 360®), and clinical outcomes of chemotherapy with the dual targeted therapy according to the intratumor HER2 heterogeneity status.
Results
Somatic alterations in ctDNA were detected in 20 of 21 (95.2%) patients. Among them, HER2-homo was observed in 8 of 20 patients (40.0%). AGC patients with HER2-homo tended to have a higher proportion of immunohistochemistry 3+ than those with HER2-hetero (100% vs 58.3%, P = 0.055), and the ERBB2 copy number variant (CNV) detection rate in HER2-homo tended to be higher than those in HER2-hetero (87.5% vs 41.7%, P = 0.07). In addition, ctDNA ERBB2 copy number in HER2-homo was significantly higher than those in HER2-hetero (4.5 copies vs 2.51 copies, P = 0.045). In contrast, the proportion of single nucleotide variant (SNV)s or CNVs associated with the cell cycle tended to be lower in HER2 homo than in HER2 hetero (25% vs 75%, P = 0.065). Regarding clinical outcomes of chemotherapy with HER2 and PD-1 dual targeted therapy, both median progression free survival (PFS) and overall survival (OS) in the HER2-homo was tended to be longer than that in the HER2-hetero (PFS: 20.8 months [95% CI] 8.4–NA] vs. 11.3 months [95% CI 5.5–16.3]; hazard ratio (HR) 0.36; 95% CI 0.11–1.24; P = 0.1, OS: NA [95% CI 14–NA] vs. 21.0 months [95% CI 10–NA]; HR 0.36; 95% CI 0.06–1.98; P = 0.24).
Conclusions
Intra-tumor HER2 heterogeneity, classified to homogenous or heterogenous, may be a useful biomarker associated with distinct tumor biology to predict the clinical efficacy of anti-HER2 and anti- PD-1 dual targeted therapy in patients with HER2 positive AGC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ono Pharmaceutical Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1937P - Clinical characteristics and prognosis of pediatric patients with papillary thyroid carcinoma
Presenter: Junko Akaishi
Session: Poster session 18
1938P - Nomogram for predicting lung metastases in patients with papillary thyroid cancer under 55 years old
Presenter: Huiyun Yang
Session: Poster session 18
1939P - BrafV600E-induced cancer inflammation in a mouse model of thyroid tumorigenesis
Presenter: Sima Kumari
Session: Poster session 18
1940TiP - Sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory thyroid carcinoma and anaplastic thyroid carcinoma: The phase II SETHY, GETNE-T2318 trial design
Presenter: Alejandro Garcia Alvarez
Session: Poster session 18
1941TiP - Neoadjuvant pembrolizumab in high-risk thyroid cancer (NePenTHe)
Presenter: Claudia Leli
Session: Poster session 18
1924P - Efficacy and safety of lenvatinib in patients with chemotherapy-naive advanced or recurrent thymic carcinoma: A multicenter retrospective study
Presenter: Daisuke Hazama
Session: Poster session 18
1923P - Real-world management and outcome of thymic carcinomas in a tertiary German center
Presenter: Antonia Margineanu
Session: Poster session 18
1922P - Targeted resequencing designed specifically for thymic epithelial tumours confirmed the high prevalence of GTF2I mutations
Presenter: Iacopo Petrini
Session: Poster session 18
1921P - Molecular analysis of mesothelioma reveals mutations as prognostic biomarkers for patients treated with the combination of ipilimumab and nivolumab
Presenter: Angelica Rigutto
Session: Poster session 18
1920P - Multiomics analysis of malignant pleural mesothelioma and the effect of immune checkpoint inhibitors
Presenter: Akiko Tateishi
Session: Poster session 18